Medical Writers News Hubb
Advertisement Banner
  • Home
  • News
  • Papers
  • Contact
No Result
View All Result
  • Home
  • News
  • Papers
  • Contact
No Result
View All Result
Wellnessnewshubb
No Result
View All Result
Home News

Cerba Research is officially a member of Hong Kong Bio-Med Innotech Association (HKBMIA)

admin by admin
January 6, 2023
in News



Cerba Research announces membership of HKBMIA to act as an advisor on speciality testing and routine clinical trials testing to advance research and health while supporting Asia pacific healthcare companies develop new therapeutics.  

HKBMIA actively introduces bio-pharmaceutical innovation technology projects from overseas and assist in various aspects, including fundraising, R&D technology, patent protection, regulations, valuation, clinical trial design and planning, contract development manufacture, project commercialization to enter Mainland China and Asia markets.  

Through collaboration with members of HKBMIA, Cerba Research aims to deepen the understanding on the role of speciality testing with a multi-specialist laboratory provider to support the research and development of new therapeutics.  

“The ambition of HKBMIA is to promote communication, exchange and cooperation amongst the biomedical innovation technology industry, research institutions, investment industry and government organizations. The understanding of Asia pacific companies regarding contract research organisations and central and speciality lab testing is limited, and the assistance that Cerba Research can provide to our bio-tech members will be decisive in helping them achieve their clinical and commercial objectives” says Professor Lo, president of HKBMIA 

“We are delighted that HKBMIA has welcomed Cerba Research into their network and look forward to sharing our expertise with China market. Our collaboration with Prof Lo and HKBMIA builds on a decade of collaboration within China and reflects our continuing ambition to facilitate research and development in the region, as well as in supporting innovative Chinese biopharmaceutical customers to expand beyond their shores” adds Daniel Tanner, Chief Commercial Officer, Cerba Research. 



Source link

Tags: HealthcareResearchTherapeutics
Previous Post

This biobattery could power devices in the small intestine

Next Post

Life Science Outsourcing acquires J-Pac Medical

Next Post

Life Science Outsourcing acquires J-Pac Medical

Recommended

Titan Medical shows off Enos surgical robot’s next-gen design

2 weeks ago

What Are the Grant Components Required for an NIH Grant?

2 weeks ago

Research maps the evolution and natural selection of E. coli bacteria

2 months ago

Positive parenting lays the foundation for close relationship with teens

4 months ago

Brazil’s ANVISA plans major medical device registration updates

4 months ago

Penn United’s advanced materials processing facility opens soon

5 months ago

Medical-Writers-(-white-)

© 2022 Medical Writers News Hubb All rights reserved.

Use of these names, logos, and brands does not imply endorsement unless specified. By using this site, you agree to the Privacy Policy and Terms & Conditions.

Navigate Site

  • Home
  • News
  • Papers
  • Contact

Newsletter Sign Up.

No Result
View All Result
  • Home
  • News
  • Papers
  • Contact

© 2022 Medical Writers News Hubb All rights reserved.